Eribulin mesylate: A novel halichondrin B analogue for the treatment of metastatic breast cancer

American Journal of Health-System Pharmacy

Volumn 69, Issue 9, 2012, Pages 745-755

  Mcbride, Ali ^a   Butler, Sara K ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Antineoplastic agents; Breast neoplasms; Eribulin mesylate; Mechanism of action; Neoplasm metastasis; Pharmacokinetics; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; ERIBULIN; GEMCITABINE; HALICHONDRIN B; NAVELBINE; TAXANE DERIVATIVE; TUBULIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BONE MARROW SUPPRESSION; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HUMAN; HYPONATREMIA; INCIDENCE; INFECTION; LEUKOPENIA; LIMB PAIN; METASTASIS; MICROTUBULE; MICROTUBULE ASSEMBLY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SPONGE (PORIFERA); VOMITING; WEIGHT REDUCTION;

EID: 84860333485     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110237     Document Type: Review

References (33)

1. Cancer facts and figures 2010. Atlanta: American Cancer Society; 2010.
2. Arriagada R, Spielmann M, Koscielny S et al. Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol. 2002; 13:1378-86.
3. Valero V, Hor tobagyi GN. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol. 2003; 21:959-62. (Pubitemid 46594120)
4. Rudas M, Filipits M, Taucher S et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat. 2003; 81:149-57. (Pubitemid 37211132)
5. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008; 34:378-90.
6. Miller KD, Chap LI, Hokmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005; 23:792-9. (Pubitemid 46224178)
7. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer. 2002; 2:143-8. (Pubitemid 37328801)
8. Simmons TL, Andrianasolo E, McPhail K et al. Marine natural products as anticancer drugs. Mol Cancer Ther. 2005; 4:333-42. (Pubitemid 40340212)
9. Ramawat KG, Goyal S. Natural products in cancer chemoprevention and chemotherapy. In: Ramawat KG, ed. Herbal drugs: ethnomedicine to modern medicine. Berlin, Germany: Springer; 2009:153-71.
10. Bai RL, Paull KD, Herald CL et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem. 1991; 266:15882-9. (Pubitemid 21907740)
11. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res . 2001; 61:1013-21. (Pubitemid 32174419)
12. Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005; 4:1086-95. (Pubitemid 41079102)
13. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4:253-65. (Pubitemid 38525281)
14. Giannakakou P, Gussio R, Nogales E et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A. 2000; 97:2904-9. (Pubitemid 30159270)
15. Bode CJ, Gupta ML Jr, Reiff EA et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry. 2002; 41:3870-4. (Pubitemid 34251025)
16. Cortes J, Montero AJ, Gluck S. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev. Epub ahead of print. 2011 May 6 (DOI 10.1016/j.ctrv.2011.03.006).
17. Smith JA, Wilson L, Azarenko O et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability . Biochemistry . 2010;49:1331-7.
18. Okouneva T, Azarenko O, Wilson L et al. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008; 7:2003-11.
19. Luduena RF, Roach MC, Prasad V et al. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol. 1993; 45:421-7. (Pubitemid 23042642)
20. Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004; 64:5760-6. (Pubitemid 39095575)
21. Halaven (eribulin mesylate) injection package insert. Woodcliff Lake, NJ: Eisai; 2010 Nov.
22. Zhang ZY, King BM, Pelletier RD et al. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol . 2008; 62:707-16.
23. Witteveen PO, Marchetti S, Mergui- Roelvink M et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. J Clin Oncol. 2010; 28:2582.
24. Tan AR, Rubin EH, Walton DC et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009; 15:4213-9.
25. Goel S, Mita AC, Mita M et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009; 15:4207-12.
26. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009; 27:2954-61.
27. Cortes J, Vahdat LT, Blum JL et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010; 28:3922-8.
28. Twelves C, Cortes J, Vahdat LT et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010; 10:160-3.
29. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet. 2011; 377:914-23.
30. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92:205-16. (Pubitemid 30099779)
31. Lee JJ, SM Swain. Peripheral neuropathy induced by microtubule- stabilizing agents. J Clin Oncol. 2006; 24:1633-42. (Pubitemid 46638788)
32. Szebeni J, Muggia FM, Alving CR. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst. 1998; 90:300-6. (Pubitemid 28182386)
33. Red book: pharmacy's fundamental reference. Montvale, NJ: Thomson PDR; 2011.